

# Overcoming Nursing Management Challenges in Metastatic Castration-Resistant Prostate Cancer

1.0  
NCPD/ILNA

Presented by:  
Kathleen D. Burns, MSN, AGACNP-BC, OCN®  
Nurse Practitioner  
Division of Genitourinary Medical Oncology  
City of Hope Comprehensive Cancer Center

Free NCPD | ILNA

## STATEMENT OF NEED

Prostate cancer is the most common tumor type affecting men in the United States. An estimated 268,490 new cases are diagnosed annually, and 34,500 people die of the disease (ACS, 2022). Typically, androgen deprivation therapy (ADT) is administered for progressive disease. However, castration resistance or unresponsiveness to ADT or antiandrogens frequently develop over time. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with limited effective treatment options. Metastatic CRPC is the primary cause of prostate cancer-related mortality and is associated with a median overall survival of less than 2 years (Seyegh et al, 2022). Therefore, it is critical for oncology nurses and others involved in the care of patients with prostate cancer to maintain up-to-date knowledge about CRPC therapies and supportive care. In this activity, Kathleen D. Burns, MSN, AGACNP-BC, OCN®, will discuss various topics relevant to the treatment of metastatic CRPC, including diagnosis, staging, and the latest clinical trial results. She will also highlight the management of drug interactions and adverse events related to novel therapies.

## TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC).

## LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

- Evaluate the diagnosis and staging of metastatic CRPC
- Appraise the efficacy and safety profiles of novel therapies for metastatic CRPC as elucidated by recent clinical trials
- Devise strategies to manage drug interactions and adverse events associated with novel therapies for metastatic CRPC

## FACULTY

Kathleen D. Burns, MSN, AGACNP-BC, OCN®  
Nurse Practitioner  
Division of Genitourinary Medical Oncology  
City of Hope Comprehensive Cancer Center

## ABOUT THE SPEAKER

Kathleen Burns, MSN, AGACNP-BC, OCN®, is a Nurse Practitioner in the Division of Genitourinary Medical Oncology at City of Hope Comprehensive Cancer Center in Duarte, California. She specializes in the treatment of patients with genitourinary malignancies, including prostate cancer and kidney cancer. In addition, Ms. Burns serves as Clinical Director for the Cancer Nurse Practitioner Fellowship at City of Hope and as Adjunct Faculty in the Graduate Nursing Program at Azusa Pacific University. She has been an invited speaker at several national conferences.

## ACCREDITATION

Provided by



## Nursing Continuing Professional Development

i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.



A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.

## Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

## REGISTRATION

There is no fee to participate in or claim NCPD credit for this activity.

Please note that i3 Health does not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.

## REQUIREMENTS FOR CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

## DOWNLOADABLE SLIDE DECK

<https://i3health.com/mcrpc#slide-deck>

## DISCLAIMER

The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient's medical condition.

## DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of an NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

### Faculty

- Kathleen D. Burns, MSN, AGACNP-BC, OCN®, discloses that she has served on an advisory board or panel for AVEO, Eisai, and Exelixis, and that she has served on a speaker's bureau for Amgen, Astellas, AstraZeneca, AVEO, Exelixis, Pfizer, and Sanofi Genzyme

### Planners and Managers

The i3 Health planners, reviewers, and managers have nothing to disclose.

i3 Health has mitigated all financial relationships.

## UNAPPROVED USE DISCLOSURE

i3 Health requires NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

## AGENDA

- I. Pre-Activity Assessment
- II. Metastatic CRPC: Diagnosis, Molecular Testing, and Staging
- III. Case Icebreaker: Current Challenges in Nursing Management of Metastatic CRPC
- IV. Novel Therapies for Metastatic CRPC: Review of Efficacy and Safety Data From Recent Clinical Trials
  - Guideline recommendations
  - Recent clinical trials: eligibility, end points, trial design, dosing/administration, safety considerations, reported outcomes
    - a. Hormonal therapies
    - b. Targeted therapies
    - c. Cytotoxic therapies
    - d. Radiopharmaceuticals
    - e. Other
- V. Managing Drug Interactions and the Safety and Tolerability of Novel Therapies for Metastatic CRPC
  - Signs and symptoms
  - Grading and assessment
  - Nursing interventions
  - Patient counseling points
- VI. Overcoming Nursing Management Challenges in Metastatic CRPC
- VII. Review of Key Learning Takeaways and Learner Q&As
- VIII. Post-Activity Assessment
- IX. 4-Week Clinical Pearls Learning Retention Email

## SUNSHINE ACT

Per the Physician Payments Sunshine Act, i3 Health is required by law to report to CMS any transfers of value (including food and beverage) provided to a covered recipient during a commercially supported educational event. Effective January 1, 2020, Physician Assistants, Nurse Practitioners, and Clinical Nurse Specialists are considered "covered recipients". All NPs and CNSs who would like to participate in the provided meal will be asked to provide all required information for reporting purposes.

## COMMERCIAL SUPPORT

This activity is supported by independent educational grants from Sanofi, Merck, and AstraZeneca.

Aggregate participant data will be shared with commercial supporters of this activity.

## AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact i3 Health prior to the live event at 973-928-8085 or at [support@i3Health.com](mailto:support@i3Health.com).

## CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at [support@i3Health.com](mailto:support@i3Health.com).